Similarly, consolidation treatment with durvalumab (with regional limitations according to PD-L1 status) after chemoradiation for unresectable locally advanced NSCLC has no regulatory limitations according to disease molecular status. The gene discussed is CD274; the disease is non-small cell lung carcinoma.